Cantor Fitzgerald reiterates Apellis stock Overweight rating with $39 target
Investing.com
Published Jul 10, 2025 07:51AM ET
Investing.com - Cantor Fitzgerald has reiterated an Overweight rating and $39.00 price target on Apellis Pharmaceuticals (NASDAQ:APLS), representing a significant upside from the current stock price of $19.21. According to InvestingPro data, analysts' targets range from $17 to $60, with a consensus Buy rating.
The firm noted that Izervay revenue increased 22% sequentially to $110 million in the second quarter compared to $91 million in the first quarter of 2025, despite vials shipped rising only an estimated 2-8%. This growth contributes to the company's impressive 48% year-over-year revenue growth, as reported by InvestingPro , which shows strong financial health metrics including a robust current ratio of 4.08.
For comparison, Cantor Fitzgerald currently models Syfovre vials shipped up 15% quarter-over-quarter with revenue also up 15%, projecting approximately $150 million in revenue, slightly below the Street's consensus of approximately $152 million according to FactSet. Get deeper insights into Apellis's financial performance with InvestingPro 's comprehensive research report, featuring detailed analysis of the company's growth trajectory and market position.
Astellas is maintaining its $750 million revenue guidance for its fiscal year 2025 (2Q25 through 1Q26) and guiding to "high 20s or above" percentage sequential revenue growth for the next three quarters, while Syfovre consensus estimates for this period are approximately $650 million per FactSet.
Astellas reported an incremental 20,000 patients treated in 2Q25 (70,000 versus 50,000 as of 1Q25, representing 40% growth), contrasting with the more modest 2-8% growth in vials shipped and 22% revenue growth.
In other recent news, Apellis Pharmaceuticals has entered into a significant royalty agreement with Swedish Orphan Biovitrum (Sobi), potentially securing up to $300 million in non-dilutive funding. The deal involves an upfront payment of $275 million and up to $25 million in milestone payments contingent on European regulatory approvals for the treatment of rare kidney diseases C3 glomerulopathy and IC-MPGN. This agreement allows Apellis to maintain its U.S. commercialization rights for systemic pegcetacoplan, marketed as EMPAVELI, and provides the company with substantial financial flexibility. Analysts from Mizuho have maintained a Neutral rating for Apellis, highlighting the strengthening of the company's balance sheet through this deal, although they express concerns about the growth prospects of Apellis's lead asset, Syfovre. Meanwhile, William Blair reiterated an Outperform rating, emphasizing the potential market share gains for Syfovre in geographic atrophy due to its efficacy. The firm also noted promising results from the VALIANT study for C3G/IC-MPGN, which could become a new revenue driver if regulatory approval is obtained. The royalty agreement includes performance-based caps, after which all ex-U.S. royalties will revert to Apellis. Apellis's CFO, Timothy Sullivan, expressed confidence in the potential of Aspaveli/EMPAVELI to transform treatment for patients with rare diseases.
Get The News You Want
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Written By: Investing.com
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.